• Voluntarily sign the informed consent and follow the requirements of the protocol;

• Age ≥18 years old;

• Expected survival time ≥3 months;

• Histologically or cytologically confirmed locally advanced or metastatic non-squamous non-small cell lung cancer;

• Documented classical EGFR mutations detected from tumor tissue or blood samples;

• Had not received any systemic therapy other than EGFR-TKIs;

• Radiographic disease progression documented during or after third-generation EGFR-TKI therapy for metastatic or locally advanced disease;

• Consent to provide archival tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 3 years;

• Must have at least one measurable lesion according to RECIST v1.1 definition;

⁃ ECOG score 0 or 1;

⁃ Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;

⁃ No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;

⁃ The level of organ function must meet the requirements on the premise that blood transfusion is not allowed within 14 days before the screening period and no cell growth factor drugs are allowed;

⁃ Coagulation function: international normalized ratio (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5×ULN;

⁃ Urine protein ≤2+ or \< 1000mg/24h;

⁃ For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the start of treatment, serum or urine must be negative for pregnancy, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.